Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
ANVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.21 - $20.00
Previous CloseN/A
Volume368.97K
Average Volume (3M)668.75K
Market Cap
$48.33M
Enterprise Value$91.95M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.65
Next Earnings
Apr 08, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding19,486,230
10 Day Avg. Volume656,156
30 Day Avg. Volume668,749
Standard Deviation0.38
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$25.00Price Target Upside982.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Annovis Bio News
PremiumCompany Announcements
Annovis Bio Launches Phase 3 Alzheimer’s Study---
Bulls Say, Bears Say
Bulls Say
Market PotentialThe stock is viewed as significantly undervalued from a longer-term perspective, due to the high unmet need in Alzheimer's disease and the large potential market.
Regulatory ApprovalThe FDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.
Study DesignAnnovis announced that the FDA has accepted the updated protocol for the pivotal P3 Alzheimer's study, allowing the company to conduct a single study, instead of two separate ones, streamlining the development timeline and likely reducing costs.
Bears Say
Capital RequirementsThe company does need to raise capital to conduct P3 trials, which may involve equity financing and non-dilutive sources through potential partnerships and grants.
Financial StrategySuccessfully navigating through funding needs remains very important to execute on its plans.
Funding NeedsThe company will need to secure additional funding to support the conduction of pivotal trials with its lead candidate, buntanetap.
---
Ownership Overview
18.88% Insiders
2.52% Mutual Funds
1.62% Other Institutional Investors
74.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $2.21 and its highest was $20.00 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $48.33M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Apr 08, 2025 which is in 46 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Nov 11, 2024. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.683 by -$0.287.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.27.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 19,486,230 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.683. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (982.25% Upside)
$25.00 (982.25% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 66%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.85%
12-Months-Change
Fundamentals
Return on Equity
-596.70%
Trailing 12-Months
Asset Growth
40.48%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
ANVS Stock 12 Month Forecast
Average Price Target
$25.00
▲(982.25% Upside)
Technical Analysis
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-51.50%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -51.50% per trade.
---